The Norwegian Institute of Public Health is carrying out an open tender contest for the procurement of vaccine preparedness against pandemic influenza on behalf of the Ministry of Health and Care Services. The objective of the procurement is to ensure that Norway's residents have access to a vaccine in the event of an influenza pandemic occurring in the contract period.

The procurement shall be carried out as an open tender contest in accordance with the Public Procurement Act Parts 1 and 3. The procurement will be carried out as an open tender competition.

The Norwegian Institute of Public Health is carrying out an open tender contest for the procurement of vaccine preparedness against pandemic influenza on behalf of the Ministry of Health and Care Services. The objective of the procurement is to ensure that Norway's residents have access to vaccines in the event of an influenza pandemic occurring during the contract period.

Based on a population of 5 525 306 people (Statistics Norway's estimate for Norway's population in 2026), and that a two-dose regimen may be necessary to ensure full immunity in the entire population, the total number of vaccine doses against pandemic influenza is 11 050 612 doses.

As described in the Call for Tender section 1.4, approximately 3.9 million doses have already been covered through the European Health Emergency Preparedness and Response Authority (HERA). The remaining need is consequently 7 101 946 doses.

The Norwegian Institute of Public Health intends to enter into contracts with two suppliers. To ensure the best possible security of supply, a limit of 50% of the total need of 11 050 612 doses has been decided for a single supplier. This means that a supplier who already has a contract for the delivery of a vaccine against pandemic influenza to Norway, can only be assigned a limited number of doses to ensure that this supplier does not exceed the limit of 50% of the total need.

The 7 101 946 vaccine doses will be divided between two contracts. One contract includes the delivery of 5 525 306 doses (50%) and the other of 1 576 640 doses, which is the remaining number of doses needed to achieve 100% coverage of the total need.

Each supplier can only be awarded one contract. Tenderers are allowed to offer a set of prices (preparedness fee and price per vaccine) for each volume. It is not mandatory to offer prices for both volumes. A tenderer can, for example, choose to submit tenders for only one volume. A tenderer that has an ongoing contract for the delivery of vaccine doses against pandemic influenza to Norway can only submit tenders for the delivery of 1 576 640 doses.

The Norwegian Institute of Public Health will award a contract for the reservation of 5 525 306 vaccine doses to the tenderer who gives the best price-quality ratio for this volume. (Supplier no. 1)

A contract of 1 576 640 vaccine doses will then be awarded to one of the remaining suppliers who has offered the best price-quality ratio for this volume (Supplier no. 2).

The contracts have an option for delivering vaccines against pandemic influenza in the contract period. The number of doses that the Norwegian Institute of Public Health will order under each volume will depend on the chosen immunization regimen and the expected severity of the pandemic.

The Norwegian Institute of Public Health emphasises that the procurement may be dependent on final approval from the Ministry of Health and Care Services and the Norwegian Parliament. The invitation to tender may be cancelled if such approval is not obtained.

A comprehensive description of the supplier requirements is given in the Call for Tender.

The Norwegian Institute of Public Health is carrying out an open tender contest for the procurement of vaccine preparedness against pandemic influenza on behalf of the Ministry of Health and Care Services. The objective of the procurement is to ensure that Norway's residents have access to vaccines in the event of an influenza pandemic occurring during the contract period.

Based on a population of 5 525 306 people (Statistics Norway's estimate for Norway's population in 2026), and that a two-dose regimen may be necessary to ensure full immunity in the entire population, the total number of vaccine doses against pandemic influenza is 11 050 612 doses.

As described in the Call for Tender section 1.4, approximately 3.9 million doses have already been covered through the European Health Emergency Preparedness and Response Authority (HERA). The remaining need is consequently 7 101 946 doses.

The Norwegian Institute of Public Health intends to enter into contract with two suppliers. To ensure the best possible security of supply, a limit of 50% of the total need of 11 050 612 doses has been decided for a single supplier. This means that a supplier who already has a contract for the delivery of a vaccine against pandemic influenza to Norway, can only be assigned a limited number of doses to ensure that this supplier does not exceed the limit of 50% of the total need.

The 7 101 946 vaccine doses will be divided between two contracts. One contract includes the delivery of 5 525 306 doses (50%) and the other of 1 576 640 doses, which is the remaining number of doses needed to achieve 100% coverage of the total need.

Each supplier can only be awarded one contract. Tenderers are allowed to offer a set of prices (preparedness fee and price per vaccine) for each volume. It is not mandatory to offer prices for both volumes. A tenderer can, for example, choose to submit tenders for only one volume. A tenderer who has an ongoing contract for the delivery of vaccine doses against pandemic influenza to Norway can only submit tenders for the delivery of 1 576 640 doses.

The Norwegian Institute of Public Health will award a contract for the reservation of 5 525 306 vaccine doses to the tenderer who gives the best price-quality ratio for this volume. (Supplier no. 1.)

A contract of 1 576 640 vaccine doses will then be awarded to one of the remaining suppliers who has offered the best price-quality ratio for this volume (Supplier no. 2).

The contracts have an option for delivering vaccines against pandemic influenza in the contract period. The number of doses that the Norwegian Institute of Public Health will order under each volume will depend on the chosen immunization regimen and the expected severity of the pandemic.

The Norwegian Institute of Public Health emphasises that the procurement may be dependent on final approval from the Ministry of Health and Care Services and the Norwegian Parliament. The invitation to tender may be cancelled if such approval is not obtained.

A comprehensive description of the supplier requirements is given in the Call for Tender.